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Abstract
Background: High-quality systems have adopted a comprehensive approach to preventive care instead of
diagnosis or procedure driven care. The current emphasis on prescribing medications to prevent complications of
coronary artery disease (CAD) at discharge following an acute coronary syndrome (ACS) may exclude high-risk
patients who are hospitalized with conditions other than ACS.
Methods: Among a sample of patients with CAD treated at Veterans Affairs medical centers between January,
2005 and November, 2006, we investigated whether recent non-ACS hospitalization was associated with
prescriptions of preventive medications as compared with patients recently hospitalized with ACS.
Results: Of 13,211 patients with CAD, 58% received aspirin, 70% b-blocker, 60% angiotensin-converting enzyme
inhibitor (ACE-I) or angiotensin II receptor blocker (ARB), and 65% lipid-lowering therapy. Twenty-five percent of
eligible patients were receiving all four medications. Having been hospitalized for a non-ACS event in the prior 6
months did not substantially affect the adjusted proportion on preventive medications. In contrast, among patients
hospitalized for ACS in the prior 6 months, the adjusted proportion prescribed aspirin was 21% higher (p < 0.001),
b-blocker was 14% higher (p < 0.001), ACE-I or ARB was 9% higher (p < 0.001), lipid therapy was 12% higher (p <
0.001), and prescribed all four medications was 18% higher (p < 0.001) than among patients hospitalized for ACS
more than 2 years earlier.
Conclusions: Being hospitalized for a non-ACS condition did not appear to influence preventive medication use
among patients with CAD and represents a missed opportunity to improve patient care. The same protocols
employed to improve use of preventive medications in patients discharged for ACS might be extended to CAD
patients discharged for other conditions as well.
Background
Strategies to improve provision of medications effective
in preventing complications of coronary artery disease
(CAD) have focused largely on patients who have just
experienced an acute coronary event [1-3]. Although
these patients represent a high risk group and ensuring
that they receive preventive medications at discharge
after an acute coronary syndrome (ACS) is important,
this strategy overlooks other opportunities that systems
and providers have to improve care for the larger group
of patients with CAD who are not experiencing ACS. For
example, it is unknown if patients hospitalized because of
an illness other than ACS have their cardiovascular medi-
cations appropriately adjusted prior to discharge.
We sought to determine if recent non-ACS hospitaliza-
tion was associated with use of preventive cardiac medi-
cations in comparison with patients admitted with ACS.
Given the emphasis on secondary prevention measures
for CAD at the time of discharge for ACS and prior stu-
dies demonstrating high rates of preventive medication
prescription at discharge for ACS [1-5], we anticipated a
large effect of recent ACS hospitalization on the propor-
tion of patients on preventive medications. Compara-
tively, we hypothesized recent non-ACS hospitalization
would have a minimal impact on the proportion of
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and represent a previously unappreciated opportunity to
improve CAD preventive care.
Methods
Data from our study were obtained from the Cardiac
Care Follow-Up Clinical Study (CCFCS) which is derived
from the External Peer Review Program for quality moni-
toring of acute myocardial infarction and unstable angina
in the Veterans Health Administration. This program
includes data on 100% of patients diagnosed with acute
myocardial infarction and a random sample of 10% of
patients diagnosed with unstable angina treated at VA
medical centers during the study period. Patients were
identified by International Classification of Diseases,
Ninth Revision (ICD-9), diagnosis codes 410.xx (myocar-
dial infarction) and 411.xx (unstable angina) from admin-
istrative data. Resulting patient lists were then
transmitted to Veterans Affairs (VA) facilities, where
both paper and electronic medical records were manually
abstracted by trained abstractors using standard report-
ing forms into the CCFCS data repository. The study was
approved by the Institutional Review Board of VA Puget
Sound. Additional details regarding CCFCS have been
described previously [6].
From patients in CCFCS admitted between January 1,
2005 and November 22, 2006, we identified patients with
a prior history of myocardial infarction, unstable angina,
or coronary atherosclerosis as determined by review of
ICD-9 diagnosis codes (410.xx, 411.xx, 412.xx, or 414.xx)
for all inpatient and outpatient visits in the 3 years prior
to the admission date. Thus, all patients within the study
cohort had a history of CAD within the 3 years preceding
the ACS hospitalization captured by CCFCS. For patients
with multiple hospitalizations captured within the
CCFCS study period, we considered the most recent hos-
pitalization as the index event. We excluded patients
with missing data regarding outpatient medications for
coronary prevention at the time of index admission.
Patients with an absolute (i.e. medication allergy) or rela-
tive contraindication to a medication were excluded from
analyses of that medication. Relative contraindications
for aspirin included use of warfarin prior to admission,
history of anemia, or history of ulcer. History of renal
failure was considered a relative contraindication to
angiotensin-converting enzyme inhibitor (ACE-I) or
angiotensin II receptor blocker (ARB) and history of liver
disease was considered a relative contraindication to use
of lipid lowering medications.
The main outcomes of interest were receipt of outpa-
tient prescriptions for preventive medications (aspirin,
b-blocker, lipid-lowering medication, and ACE-I or
ARB) as determined from chart review of the admission
records at the time of index hospitalization for ACS in
the CCFCS registry. The exposures of interest were the
time interval from prior non-ACS and ACS hospitaliza-
tions in the VA to the index event. For each patient, a
time since prior non-ACS hospitalization and time since
prior ACS hospitalization was determined separately.
These intervals were determined by review of all dis-
charges from VA health care in the two years preceding
the index event and measured from the date of dis-
charge to the date of admission for the index event. Pre-
vious hospitalizations were determined to have been for
ACS if the primary diagnosis code was myocardial
infarction, unstable angina, or coronary atherosclerosis
(ICD-9 of 410.XX, 411.XX, 412.XX, or 414.XX) [7].
When the discharge date for the previous hospitalization
and index admission date were the same, as in the case
of patient transfer from another facility, the preceding
hospitalization was considered for this interval. We
grouped these intervals into ≤ 6 months, 6-12 months,
12-24 months, and > 24 months since last hospitalized.
These intervals were chosen to maximize sample size in
the comparison intervals prior to 2 years.
We used data from the CCFCS data registry to
describe demographic and personal characteristics (i.e.
age, sex, current smoker, hypertension, diabetes, heart
failure, cerebral vascular disease, peripheral vascular dis-
ease, chronic kidney disease, and chronic obstructive
pulmonary disease). Ethnicity was based on a combina-
tion of self-report and the electronic record [8]. Socioe-
conomic status was based on the VA means test [9].
We present unadjusted descriptive summaries of base-
line patient characteristics for the study cohort. We
report unadjusted descriptive statistics of the proportion
of eligible patients on individual medications and multi-
ple medications by patient characteristics. We conducted
analyses separately for each individual medication and
cumulative medications of interest as the eligible popula-
tion varied due to contraindications to therapies.
We anticipated missing values for our ethnicity covariate
[8]. Instead of ignoring missing data using complete-case
analysis, we conservatively chose to impute missing covari-
ate values with chained equations. This method provides
less biased estimates than complete-case analysis [10].
From the imputed data, multivariate logistic regression
estimated the effect size of time interval since hospitaliza-
tion for non-ACS and ACS episodes on the prescription of
preventive medications prior to recurrent event after
adjustment for other covariates [11]. Our model included
both exposures of interest and the following covariates:
age (< 55, 55-65, 65-75, ≥ 75 as indicator variables), sex,
ethnicity, socioeconomic status (low, middle, high as indi-
cator variables), current smoker, hypertension, diabetes,
heart failure, cerebral vascular disease, peripheral vascular
disease, chronic kidney disease, and chronic obstructive
pulmonary disease. We did not perform hypothesis testing
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sion analyses, but instead included standard covariates
that have been associated with preventive medication use
in a prior analysis [12]. We also included age and socioe-
conomic status as indicator variables to allow for non-lin-
ear associations between these variables and preventive
medication use. From our logistic regression results, we
report the proportion of patients prescribed medications
for the exposure of interest adjusted to reflect the mean
for each covariate in the cohort. This was determined for
each level of the predictor of interest by calculation of the
log odds and standard error within each imputed dataset,
combination of log odds and standard errors across data-
sets using methods described by Rubin,[13] and transfor-
mation of log odds and standard errors to proportions and
confidence intervals. We report adjusted proportions or
percentages in place of odds ratios as our outcome was
common and odds ratios do not approximate relative risks
in this setting [14,15].
We conducted a number of sensitivity analyses to
evaluate the robustness of our findings. First, we
repeated our analyses after excluding patients with a his-
tory of dementia or cancer as providers may have antici-
pated less benefit to preventive therapies in this setting.
We then repeated our analyses after stratifying on past
history of myocardial infarction. This stratified analysis
was to ensure any observed effect size in the primary
analysis was not related to inclusion of low-risk patients
with a remote history of ACS. We next explored the
potential for bias related to exclusion of patients with
incomplete ascertainment of preventive medication his-
tory. Finally, we completed a complete-case analysis to
estimate the influence of imputation on our results. All
statistical analyses were conducted with Stata, version
10.0 (StatCorp LP, College Station, TX). All hypotheses
were evaluated at a two-sided significance level of 0.05,
with calculation of 95% confidence intervals.
Results
There were 22,223 patients admitted for ACS during the
study period, of whom, 14,252 (64%) had a diagnosis of
CAD within the previous 3 years. We excluded 1,041
(7%) patients whose medications were not assessed at
t h et i m eo fa d m i s s i o n .A f t e rexclusion of patients with
absolute or relative contraindications, 10,296 (78%)
patients were deemed eligible to receive aspirin, 13,148
(> 99%) b-blockers, 10,367 (78%) ACE-I or ARB, 12,949
lipid-lowering therapy, and 8,267 (63%) were eligible for
all four medications (Figure 1).
The patients studied were largely elderly, white men
(Table 1). Ethnicity was missing for 25% of patients as
anticipated from prior studies using similar VA data
sources [8]. Data were complete for all other covariates.
Nearly 50% of the cohort had been hospitalized for a
non-ACS event in the previous 2 years, while less than
25% had been hospitalized for ACS during that time
frame.
b-blockers were the most commonly prescribed pre-
ventive medication (70% of eligible patients), while lipid-
lowering therapy was prescribed in nearly 65%, ACE-I
or ARB in 60%, and aspirin in 58% of eligible patients
(Table 2). Only 25% of patients eligible for all four med-
ications were prescribed the full combination of preven-
tive therapies. A higher proportion of patients were on
all four medications if they had a prior history of revas-
cularization by PCI or CABG, or if they had a history of
hypertension, hyperlipidemia, diabetes, or heart failure.
The adjusted proportion of eligible patients on preven-
tive medications by time since last hospitalization is
shown in Figure 2, stratified by time since prior hospitali-
zation for non-ACS (Figure 2A) and ACS hospitalization
(Figure 2B). The adjusted proportion of eligible patients
on secondary preventive medications was influenced only
minimally by recent non-ACS hospitalization. Among
patients hospitalized during the past 6 months for a non-
ACS event, the proportion prescribed aspirin was 5%
higher (p < 0.001), b-blockers was 2% (p = 0.02) higher,
the proportion on ACE-I or ARB was 3% (p = 0.04)
lower, on lipid-lowering therapy was 4% (p < 0.001)
lower, and on all four medications was 1% higher (p =
0.86) compared with patients not hospitalized for a non-
ACS event in the past 2 years.
Recent hospitalization for ACS was associated with a
higher likelihood of receiving preventive medications. The
adjusted proportion on aspirin was 21% higher (p < 0.001),
b-blockers was 14% higher (p < 0.001), on ACE-I or ARB
was 9% higher (p < 0.001), on lipid-lowering therapy was
12% higher (p < 0.001), and on all four medications was
18% higher (p < 0.001) compared with patients hospita-
lized for ACS more than 2 years ago (Table 3).
In sensitivity analyses, excluding patients with a history
of dementia (n = 2,291) or cancer (n = 926) increased the
Figure 1 Identification of Study Cohort. CAD = coronary artery
disease; ACE-I = angiotensin-converting enzyme inhibitor, ARB =
angiotensin II receptor blocker, Meds = medications.
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by approximately 1%, but no appreciable change was
noted in the proportion of patients on preventive medi-
cations by time since last non-ACS or ACS hospitaliza-
tion (Table 4). Similarly, stratification on history of
myocardial infarction did not substantially change the
results (Table 5). In our study, we intentionally limited
our analysis time frame to the period that included data
on ARB use within CCFCS to minimize misclassification
of ACE-I or ARB use as an outcome. Despite this restric-
tion, missingness on ARB use constituted 997 (> 99%) of
the patients excluded in our analysis. Our findings were
unchanged in an analysis of preventive medications other
than ACE-I or ARB in the expanded cohort that included
patients with missingness on ARB use. Finally, our com-
plete-case analysis suggested our results were minimally
influenced by our imputation technique (Table 6).
Discussion
In our cohort, recent non-ACS hospitalization was not
associated with a substantial difference in preventive
medication use in patients with known CAD. Non-ACS
hospitalizations represent a potential missed opportunity
to improve preventive care of patients with CAD. This
is evidenced by the 10-20% increase in use of preventive
medications among patients recently hospitalized for
ACS.
Since 2003, more than 90% of patients treated within
the VA health care system were discharged on preventive
medications after ACS [4]. The quality measures asso-
ciated with this success do not currently apply to CAD
patients with non-ACS hospitalizations [1-3]. This is of
particular importance in light of the proportion of
patients admitted for non-ACS diagnoses prior to the
index event. While less than 25% of our cohort had been
hospitalized for ACS during the past 2 years, nearly 50%
had been hospitalized for other diagnoses in that period.
Targeting hospitalization as an opportunity to improve
preventive care has been demonstrated in efforts to
increase influenza and pneumococcal vaccination
[16-18]. A similar approach targeting all hospitalized
CAD patients has the potential to increase the proportion
of patients who receive preventive medications and
thereby prevent recurrent ACS events.
The importance of utilizing all care episodes to
improve comprehensive patient care is underscored by
recent national health legislation that supports accounta-
ble care organizations whereby providers are jointly held
accountable for achieving quality improvement measures
and reducing the rate of spending growth [19-21]. Opti-
mizing preventive medications on discharge after non-
ACS hospitalizations would potentially impact providers
and systems by reducing hospitalizations that would be
uncompensated in an accountable care model. In addi-
tion, initiation of preventive CAD medications in patients
after non-ACS hospitalizations may increase the propor-
tion of patients achieving proposed quality measures
such as goal cholesterol levels [22].
Despite 90% of patients being prescribed preventive
medications on discharge for ACS, we observed only 68 to
82% of eligible patients were taking individual preventive
medications 6 months after ACS. This is consistent with
prior studies that have demonstrated medication nonad-
herance is common after discharge for ACS [23-29].
Although prescribing medications for CAD after non-ACS
hospitalizations would increase the proportion of patients
Table 1 Baseline Patient Characteristics of Analysis
Cohort
Characteristic Entire Cohort
(n = 13,211)
Age (yrs)
< 55 1,162 (8.8%)
55-65 3,900 (29.5%)
65-75 3,209 (24.3%)
≥ 75 4,940 (37.4%)
Female 169 (1.3%)
Ethnicity
White 7,461 (56.5%)
Non-white 2,105 (15.9%)
Unknown 3,645 (27.6%)
Socioeconomic status
Low 6,875 (52.0%)
Middle 4,917 (37.2%)
High 1,419 (10.7%)
Current smoker 3,190 (24.2%)
Coronary artery bypass grafting 4,087 (30.9%)
Percutaneous coronary intervention 3,042 (23.0%)
Hypertension 9,360 (70.9%)
Hyperlipidemia 9,512 (72.0%)
Diabetes 2,373 (18.0%)
Heart failure 5,513 (41.7%)
Cerebral vascular disease 1,019 (7.7%)
Peripheral vascular disease 2,028 (15.4%)
Chronic kidney disease 2,398 (18.2%)
Chronic obstructive pulmonary disease 2,515 (19.0%)
Time interval since ACS hospitalization
≥ 6 months 1,623 (12.3%)
6-12 months 616 (4.7%)
12-24 months 779 (5.9%)
> 24 months 10,193 (77.2%)
Time interval since non-ACS hospitalization
≤ 6 months 3,460 (26.2%)
6-12 months 1,248 (9.5%)
12-24 months 1,343 (10.2%)
> 24 months 7,160 (54.2%)
Data was complete for all covariates with the exception of ethnicity.
ACS = acute coronary syndrome.
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Characteristic Prescribed Medication, %
(n = Eligible Patients)
Aspirin
(n = 10,296)
B-blocker
(n = 13,148)
ACE-I/ARB
(n = 10,367)
Lipid lowering
(n = 12,949)
All Meds
(n = 8,267)
All eligible patients 58.3 70.2 60.3 64.8 25.0
Age (yrs)
< 55 58.0 65.6 54.3 61.5 23.5
55-65 59.3 70.3 60.4 66.8 28.3
65-75 56.2 73.9 64.6 69.2 25.7
≥ 75 59.0 68.8 58.9 61.2 21.3
Female 57.6 67.3 60.5 63.3 20.2
Ethnicity
White 60.1 71.7 60.9 66.2 26.1
Non-white 60.9 69.3 63.6 62.8 25.7
Unknown 53.5 67.7 57.3 63.0 22.6
Socioeconomic status
Low 57.2 70.3 60.8 63.9 24.4
Middle 62.1 70.9 60.3 65.0 26.5
High 50.9 67.3 57.4 68.0 22.5
Current smoker 56.3 66.4 55.9 63.0 23.8
CABG 63.3 79.1 66.5 75.0 32.8
PCI 65.3 77.2 65.4 72.9 32.4
Hypertension 59.1 72.1 64.4 66.7 26.6
Hyperlipidemia 59.7 72.7 62.6 70.6 27.4
Diabetes 62.4 76.3 70.7 68.8 29.8
Heart failure 61.9 76.8 70.0 67.3 30.9
Cerebral vascular disease 59.1 71.2 63.3 66.0 24.5
Peripheral vascular disease 61.1 73.4 64.3 67.5 25.9
Chronic kidney disease 59.2 76.4 60.9 67.5 27.4
COPD 57.7 67.2 59.7 63.5 22.7
Data was complete for all covariates with the exception of ethnicity. ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker;
CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention; COPD = chronic obstructive pulmonary disease.
Figure 2 Adjusted Proportion on Preventive Medications by Time Interval Since Prior Hospitalization. A. Adjusted Proportion on
Medications by Time Interval Since Last ACS Hospitalization* B. Adjusted Proportion on Medications by Time Interval Since Last N-ACS
Hospitalization
†. *Adjusted for age, sex, race, socioeconomic status, current smoker, hypertension, diabetes, congestive heart failure, cerebral
vascular disease, peripheral vascular disease, chronic kidney disease, and time since non-ACS hospitalization. † Adjusted for covariates as above
with time since ACS hospitalization in place of time since non-ACS hospitalization. ‡ p < 0.05 compared to < 6 months. § p < 0.01 compared to
< 6 months. ‖ p < 0.001 compared to < 6 months.
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Page 5 of 12Table 3 Proportion on Preventive Medications by Time Interval Since Last Hospitalized
Medication
(n = Eligible Patients)
Aspirin
(n = 10,296)
b-blocker
(n = 13,148)
ACE-I/ARB
(n = 10,367)
Lipid Lowering
(n = 12,949)
All Meds
(n = 8,267)
Time Interval
Since
ACS
Hospitalization
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
< 6 months 77 (75-80) 76 (74-79) 83 (81-85) 82 (80-84) 70 (67-73) 68 (66-71) 75 (73-77) 75 (73-77) 42 (39-45) 39 (36-42)
6-12 months 73 (69-77) 71 (66-75)
‡ 86 (83-88) 84 (80-87) 70 (66-74) 68 (63-72) 74 (70-77) 72 (68-76) 39 (34-44) 34 (29-39)
12-24 months 64 (60-68)
|| 62 (58-66)
|| 80 (77-83) 78 (75-81)
‡ 74 (70-77) 72 (68-75) 74 (71-77) 72 (69-75) 36 (31-40)
‡ 31 (27-35)
§
> 24 months 54 (53-55)
|| 55 (54-56)
|| 66 (66-67)
|| 68 (68-69)
|| 57 (56-58)
|| 59 (58-60)
|| 62 (61-63)
|| 63 (62-64)
|| 21 (20-22)
|| 21 (20-22)
||
Time Interval
Since
Non-ACS
Hospitalization
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
< 6 months 63 (62-65) 63 (61-65) 73 (72-75) 73 (72-75) 61 (59-62) 59 (57-61) 62 (60-64) 63 (61-65) 26 (24-28) 23 (21-25)
6-12 months 60 (57-63) 59 (56-62) 73 (70-75) 72 (70-75) 64 (61-67) 62 (59-66) 65 (63-68)
‡ 66 (63-69) 26 (23-29) 23 (20-26)
12-24 months 57 (54-60)
|| 57 (54-60)
§ 71 (69-73) 72 (69-74) 60 (57-63) 60 (57-63) 64 (61-66) 64 (62-67) 26 (23-29) 23 (21-27)
> 24 months 56 (55-57)
|| 58 (56-59)
|| 68 (67-69)
|| 71 (70-72)
‡ 60 (58-61) 62 (61-63)
‡ 66 (65-67)
|| 67 (66-69)
|| 24 (23-26) 24 (22-25)
*Adjusted for age, sex, race, socioeconomic status, current smoker, hypertension, diabetes, congestive heart failure, cerebral vascular disease, peripheral vascular disease, chronic kidney disease, and time since non-
ACS hospitalization.
†Adjusted for covariates as above with time since last ACS hospitalization in place of time since non-ACS hospitalization.
‡ p < 0.05 compared to < 6 months.
§ p < 0.01 compared to < 6 months.
|| p < 0.001 compared to < 6 months.
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2Table 4 Proportion on Preventive Medications by Time Interval Since Last Hospitalized After Exclusion of Patients with History of Dementia or Cancer
Medication
(n = Eligible Patients)
Aspirin
(n = 7,984)
b-blocker
(n = 9,941)
ACE-I/ARB
(n = 7,876)
Lipid Lowering
(n = 9,824)
All Meds
(n = 6,452)
Time Interval
Since
ACS
Hospitalization
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
< 6 months 77 (75-80) 76 (73-79) 84 (82-86) 83 (81-85) 71 (68-74) 70 (66-73) 75 (73-78) 75 (73-78) 44 (40-47) 40 (37-44)
6-12 months 73 (68-77) 71 (66-75) 86 (83-89) 84 (80-87) 72 (67-76) 69 (64-74) 74 (70-78) 73 (68-77) 39 (34-45) 35 (29-41)
12-24 months 64 (60-68)
|| 62 (57-66)
|| 80 (77-83) 78 (74-81)
‡ 76 (71-80) 74 (69-78) 74 (70-78) 72 (68-76) 35 (30-40)
§ 30 (26-35)
§
> 24 months 54 (53-55)
|| 55 (53-56)
|| 68 (67-69)
|| 70 (69-71)
|| 58 (57-60)
|| 60 (59-61)
|| 64 (63-65)
|| 66 (65-67)
|| 22 (20-23)
|| 21 (20-22)
||
Time Interval
Since
Non-ACS
Hospitalization
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
< 6 months 65 (63-67) 64 (61-67) 76 (74-77) 75 (73-77) 63 (60-65) 60 (58-63) 64 (62-66) 65 (63-67) 28 (25-31) 25 (22-27)
6-12 months 60 (57-64)
‡ 59 (55-63)
‡ 76 (73-78) 75 (71-78) 67 (63-70) 64 (60-68) 69 (66-72)
‡ 69 (65-72) 27 (23-31) 23 (19-27)
12-24 months 57 (53-61)
|| 56 (53-60)
§ 74 (71-76) 74 (71-77) 63 (59-66) 62 (58-66) 66 (63-69) 67 (63-70) 27 (23-31) 24 (21-28)
> 24 months 56 (55-57)
|| 57 (56-59)
|| 69 (67-70)
|| 72 (70-73)
§ 60 (59-61) 63 (61-64) 67 (66-68)
‡ 69 (67-70)
‡ 25 (23-26)
‡ 24 (23-26)
*Adjusted for age, sex, race, socioeconomic status, current smoker, hypertension, diabetes, congestive heart failure, cerebral vascular disease, peripheral vascular disease, chronic kidney disease, and time since non-
ACS hospitalization.
†Adjusted for covariates as above with time since last ACS hospitalization in place of time since non-ACS hospitalization.
‡ p < 0.05 compared to < 6 months.
§ p < 0.01 compared to < 6 months.
|| p < 0.001 compared to < 6 months.
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2Table 5 Proportion on Preventive Medications by Time Interval Since Last Hospitalized Limited to Patients with Past History of Myocardial Infarction After
Exclusion of Patients with History of Dementia or Cancer
Medication
(n = Eligible Patients)
Aspirin
(n = 4,691)
b-blocker
(n = 5,830)
ACE-I/ARB
(n = 4,603)
Lipid Lowering
(n = 5,757)
All Meds
(n = 3,794)
Time Interval
Since
ACS
Hospitalization
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
< 6 months 79 (76-81) 77 (74-80) 84 (82-86) 83 (81-86) 71 (67-74) 69 (66-73) 75 (72-78) 75 (72-78) 43 (39-47) 39 (35-44)
6-12 months 72 (67-77)
‡ 70 (64-75)
‡ 87 (83-90) 86 (81-89) 72 (66-77) 69 (63-75) 74 (69-78) 72 (66-77) 40 (33-47) 35 (29-42)
12-24 months 65 (60-70)
|| 63 (57-68)
|| 81 (76-84) 78 (73-82)
‡ 74 (69-79) 72 (66-77) 72 (67-76) 70 (64-74) 37 (31-43) 33 (27-39)
> 24 months 55 (54-57)
|| 57 (55-58)
|| 67 (65-68)
|| 70 (68-71)
|| 58 (57-60)
|| 60 (58-62)
|| 63 (62-65)
|| 65 (64-67)
|| 23 (21-24)
|| 23 (21-24)
||
Time Interval
Since
Non-ACS
Hospitalization
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
< 6 months 70 (67-73) 68 (65-71) 78 (76-80) 77 (75-80) 64 (60-67) 61 (57-64) 66 (64-69) 67 (64-70) 33 (29-37) 29 (25-32)
6-12 months 62 (57-66)
§ 59 (54-64)
§ 76 (72-80) 75 (70-78) 65 (60-70) 61 (55-66) 69 (65-73) 69 (64-73) 29 (24-34) 24 (19-29)
12-24 months 60 (55-64)
|| 58 (54-63)
§ 75 (71-78) 75 (71-78) 66 (62-71) 65 (60-70) 66 (62-70) 65 (61-69) 31 (26-36) 26 (22-31)
> 24 months 58 (56-60)
|| 60 (58-62)
|| 68 (67-70)
|| 73 (71-74)
§ 60 (58-62) 63 (61-65) 66 (64-67) 68 (66-69) 26 (24-27)
|| 26 (24-27)
*Adjusted for age, sex, race, socioeconomic status, current smoker, hypertension, diabetes, congestive heart failure, cerebral vascular disease, peripheral vascular disease, chronic kidney disease, and time since non-
ACS hospitalization.
†Adjusted for covariates as above with time since last ACS hospitalization in place of time since non-ACS hospitalization.
‡ p < 0.05 compared to < 6 months.
§ p < 0.01 compared to < 6 months.
|| p < 0.001 compared to < 6 months.
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2Table 6 Complete-case Analysis of Proportion on Preventive Medications by Time Interval Since Last Hospitalized
Medication
(n = Eligible Patients)
Aspirin
(n = 7,311)
b-blocker
(n = 9,524)
ACE-I/ARB
(n = 7,383)
Lipid Lowering
(n = 9,370)
All Meds
(n = 8,267)
Time Interval
Since
ACS
Hospitalization
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)*
< 6 months 78 (75-81) 77 (74-80) 82 (80-84) 82 (79-84) 69 (66-72) 68 (64-71) 74 (72-77) 74 (72-77) 41 (38-45) 38 (34-42)
6-12 months 73 (68-78) 71 (66-76)
‡ 85 (82-88) 84 (80-87) 71 (66-76) 70 (64-74) 74 (70-78) 73 (68-77) 39 (33-45) 35 (29-41)
12-24 months 66 (62-71)
|| 65 (60-69)
|| 81 (77-84) 79 (75-82) 75 (71-79)
‡ 74 (69-78)
‡ 74 (70-77) 73 (69-76) 38 (33-43) 34 (29-39)
> 24 months 56 (55-57)
|| 57 (56-58)
|| 68 (67-69)
|| 70 (68-71)
|| 59 (57-60)
|| 60 (59-61)
|| 63 (62-64)
|| 64 (63-65)
|| 22 (21-23)
|| 22 (20-23)
||
Time Interval
Since
Non-ACS
Hospitalization
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
Unadjusted
Proportion
(95% CI)
Adjusted
Proportion
(95% CI)
†
< 6 months 65 (62-67) 64 (62-66) 73 (71-74) 73 (71-75) 60 (58-63) 59 (57-62) 61 (60-63) 63 (61-65) 25 (23-28) 23 (21-25)
6-12 months 61 (57-64) 61 (57-64) 73 (70-75) 73 (70-76) 64 (60-67) 63 (59-67) 66 (63-69)
§ 67 (64-70)
‡ 26 (23-30) 24 (20-27)
12-24 months 59 (55-62)
§ 59 (56-62)
‡ 71 (68-74) 72 (69-75) 61 (58-64) 61 (58-65) 63 (60-66) 64 (61-67) 27 (24-30) 25 (21-28)
> 24 months 58 (57-60)
|| 60 (58-61)
§ 70 (69-71)
‡ 73 (71-74) 62 (60-63) 64 (62-65)
§ 68 (67-69)
|| 69 (67-70)
|| 26 (25-28) 25 (24-27)
*Adjusted for age, sex, race, socioeconomic status, current smoker, hypertension, diabetes, congestive heart failure, cerebral vascular disease, peripheral vascular disease, chronic kidney disease, and time since non-
ACS hospitalization.
†Adjusted for covariates as above with time since last ACS hospitalization in place of time since non-ACS hospitalization.
‡ p < 0.05 compared to < 6 months.
§ p < 0.01 compared to < 6 months.
|| p < 0.001 compared to < 6 months.
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2provided the opportunity to take cardioprotective medica-
tions, reducing patient non-adherence to these medica-
tions remains a significant barrier to optimal risk
reduction.
The benefit of preventive medications is influenced by
the risk of coronary events in follow-up. Furthermore, in
some patients the benefit of preventive therapies may be
mitigated by comorbid conditions such as dementia or
cancer. We conducted several sensitivity analyses to
minimize the possibility that the observed effects of time
since ACS or non-ACS hospitalization on preventive
medication use were influenced by these factors. Exclu-
sion of patients with dementia or cancer did not influ-
ence the effect size of time since ACS hospitalization or
non-ACS hospitalization. In our primary analysis, we
included patients with a history of coronary atherosclero-
sis but no history of myocardial infarction or unstable
angina. This may have resulted in the inclusion of
patients with coronary disease at lower risk of ischemic
events. Stratification of our analysis according to history
of past myocardial infarction did not influence the effect
size of time since ACS hospitalization or non-ACS hospi-
talization. This suggests the observed association is unli-
kely to merely a function of including low-risk patients
with a remote history of a coronary event. While the long
term benefit of b-blockers after ACS or the benefit of
ACE-I or ARB in CAD patients at lower risk of recurrent
events is debated,[30] the stability of our findings across
all medication classes suggest an important effect of time
since ACS hospitalization on preventive medication use
that is not apparent with non-ACS hospitalization.
Strengths of our study include 100% inclusion of
patients with AMI, large sample size, geographic diver-
sity, and the ability to assess the impact of prior ACS
and non-ACS care episodes on preventive care. Our
study has several limitations. First, the time interval
since last hospitalization was determined from previous
admissions to VA health care. As a result, there is a
potential for misclassification of time since hospitaliza-
tion for patients previously hospitalized in non-VA set-
tings. If patients recently admitted to non-VA hospitals
for ACS are also more likely to be prescribed preventive
medications, this misclassification would be expected to
bias the observed effect of recent ACS hospitalization
toward the null. Second, there is potential for misclassi-
fication of aspirin use related to the ability to obtain
aspirin without a prescription. The similar effect of time
since discharge on prescription of all classes of second-
ary preventive medications provides reassurance this did
not overly influence our findings. Third, the CCFCS
data registry does not separate statin medications from
other lipid lowering therapies. Studies of lipid lowering
therapy in secondary prevention of CAD have focused
on statin medications and our results may overestimate
the proportion of patients on lipid lowering therapy
with greatest evidence of benefit. Fourth, our use of
administrative data may have led to misclassification of
past CAD history. We were inclusive of a range of ICD-
9 codes for coronary disease in our main analysis, but
restriction to history of myocardial infarction suggests
this did not overly influence our results. Fifth, our study
is limited to patients of VA medical centers. Previous
studies have demonstrated patients receiving care within
the VA receive recommended preventive care more
often than patients covered by other health care systems
[31,32]. Studies to update knowledge on remaining gaps
in secondary prevention of CAD in non-VA settings
should be considered. Sixth, our cohort of CAD patients
may have included those with a myocardial infarction
secondary to either increased oxygen demand or
reduced supply as opposed to acute plaque rupture [33].
Although this type of myocardial infarction is less com-
mon,[6] the relative benefit to secondary preventive
medications for CAD in these patients is unclear.
Further, our exclusion criteria for use of preventive
medications were dependent on administrative diagnos-
tic codes, however we were intentionally broad in our
exclusion criteria to ensure all patients were reasonable
candidates for secondary preventive medications. Finally,
our analysis did not include covariates for other pro-
cesses of care that may influence use of preventive med-
ications. Prior studies have suggested early outpatient
follow-up after ACS [28] and subspecialty care [4] may
influence use of preventive medications. Understanding
the interplay of all care processes may help in designing
best strategies to improve preventive care for CAD.
Conclusions
Preventive medications for coronary artery disease are
critically important in reducing ischemic events and
death. While significant strides have been made to
improve the provision of these medications at discharge
after ACS, our analysis suggests this strategy fails to
o p t i m i z et h ep r e v e n t i v ec a r eo fp a t i e n t sd i s c h a r g e df o r
non-coronary events. Consideration should be given to
expanding the scope of preventive measures currently
targeted at discharge for ACS to all care episodes for
patients with coronary disease.
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